Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM G&A

Discontinued — last reported Q3 '17

G&A at other companies

Aardvark Therapeutics, Inc. logo
Aardvark Therapeutics, Inc.AARD
$5.9M+117%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.98M-0.7%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$8.79M+113%

Segments

By segment

See full
Single reportable segment$7.89M-1.2%

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K—
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$7.62B+27.5%
Enterprise value$7.67B+28.8%
P/S35.1×-3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed November 14, 2017. Open the filing →

Filed
Nov 14, 2017, 7:38 AM EST
Fiscal quarter
Q3 FY2017
Calendar quarter
Q3 2017
Accession
0001558370-17-008882

FAQ

What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.